Occam's UK TechBio Recruiting Team Places CCO for Basecamp Research

In October 2024, Occam Global recruited Anupama Hoey as Chief Commercial Officer (CCO) of London Techbio firm Basecamp Research.

‍

Hoey brings more than 20 years of experience in financing, business development, corporate strategy, drug discovery, and research and development within the life sciences.  Before joining Basecamp, she served as Chief Operating and Business Officer at Fountain Therapeutics and CBO at Sensei Biotherapeutics, where she played a crucial role in Sensei’s successful $152M IPO. Before Sensei, Hoey was the CBO of Second Genome, where she executed a multi-program drug discovery and biomarker deal with Gilead worth up to $1.5B.

‍

_{About Basecamp Research}

‍

Basecamp Research is solving the most pressing challenges in the life sciences by exploring beyond known biology. The company builds foundational AI models on top of the world’s largest, ethically sourced database of biological information to give AI the most complete understanding of biology ever. This allows for the design of biological systems of unrivaled complexity with performance improving dramatically as AI sees more diversity and context. Basecamp Research collaborates with biopharma companies and academic research institutions to design novel protein sequences and biological systems that can transform therapeutic research and development.

‍

In October 2024, Basecamp Research announced a $60M Series B Financing led by Singular, with additional investors including S32, redalpine, André Hoffmann, Vice-Chairman of Roche, Feike Sijbesma, Chair of Royal Philips and Former CEO of DSM, and Paul Polman, former CEO of Unilever. Returning investors participating in the Series B include True Ventures and Hummingbird Ventures.

‍

Concurrent with the equity financing, the company announced a multi-year collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard to develop novel fusion proteins and other large molecules to enable the next generation of genetic medicines.